Clinical trial
Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers
NCT00448890 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00448890 |
|---|---|
| Title | Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers |
| Official title | Single-Blind, Randomised, Placebo-Controlled Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Escalating Doses and Repeat Doses of GSK729327 in Healthy Volunteers |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | GSK729327, Placebo |
| Enrollment | 79 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Mar 19, 2007 |
| Last update posted | Oct 15, 2010 |
| Countries | Germany, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: